跳至主要内容
临床试验/NL-OMON55211
NL-OMON55211招募中不适用

Quantitative-imaging in cardiac transthyretin amyloidosis (I-CARE) - i-CARE

niversitair Medisch Centrum Groningen0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Completion of informed consent • Age > 18 years • ATTR cardiac amyloid
  • according to Expert Consensus Recommendations • AL amyloidosis according to
  • Expert Consensus Recommendations • Hypertrophic cardiomyopathy according to
  • European Society of Cardiology guidelines

排除标准

  • Inability or unwilling to give informed consent
  • Women who are pregnant, breastfeeding or of child-bearing potential (women
  • experienced menarche, are pre-menopausal and have not been sterilised)
  • will not be enrolled
  • into the trial.
  • Renal dysfunction (eGFR <=30 mL/min/1.73m2)
  • NYHA Class IV heart failure
  • Patients with atrial fibrillation and poor rate control.
  • Contraindications to MR
  • Previous history of contrast allergy of adverse reactions (gadolinium)
  • Contraindications to Tafamidis therapy
  • With regards to patient exclusion for solely 1[23I]MIBG scan:
  • Tricyclic antidepressants (TCA) usage (most importantly amitriptyline,
  • clomipramine, imipramine, nortriptyline, chlorpromazine or perphenazine);
  • Parkinson*s disease as mentioned in patients* medical history;
  • Insulin dependent diabetes mellitus as shown in patients* actual medication

研究者

相似试验